United Therapeutics Corp (UTHR)
235.00
-2.00
(-0.85%)
USD |
NASDAQ |
Apr 25, 11:42
United Therapeutics Cash from Financing (TTM): -11.90M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.90M |
| September 30, 2023 | 136.40M |
| June 30, 2023 | 135.80M |
| March 31, 2023 | 135.00M |
| December 31, 2022 | 75.40M |
| September 30, 2022 | 27.40M |
| June 30, 2022 | 37.00M |
| March 31, 2022 | 23.70M |
| December 31, 2021 | 44.80M |
| September 30, 2021 | 43.40M |
| June 30, 2021 | 32.40M |
| March 31, 2021 | 43.40M |
| December 31, 2020 | -16.90M |
| September 30, 2020 | -173.00M |
| June 30, 2020 | -226.90M |
| March 31, 2020 | -248.10M |
| December 31, 2019 | 611.20M |
| September 30, 2019 | 761.30M |
| June 30, 2019 | 812.00M |
| March 31, 2019 | 804.80M |
| December 31, 2018 | 6.30M |
| September 30, 2018 | 8.00M |
| June 30, 2018 | 9.10M |
| March 31, 2018 | 19.50M |
| December 31, 2017 | 43.30M |
| Date | Value |
|---|---|
| September 30, 2017 | -60.20M |
| June 30, 2017 | -196.00M |
| March 31, 2017 | -340.10M |
| December 31, 2016 | -497.70M |
| September 30, 2016 | -409.80M |
| June 30, 2016 | -319.40M |
| March 31, 2016 | -424.60M |
| December 31, 2015 | -447.00M |
| September 30, 2015 | -672.54M |
| June 30, 2015 | -703.22M |
| March 31, 2015 | -640.28M |
| December 31, 2014 | -576.60M |
| September 30, 2014 | -328.37M |
| June 30, 2014 | -241.40M |
| March 31, 2014 | -87.73M |
| December 31, 2013 | -5.115M |
| September 30, 2013 | -63.99M |
| June 30, 2013 | -113.33M |
| March 31, 2013 | -170.57M |
| December 31, 2012 | -169.14M |
| September 30, 2012 | -367.66M |
| June 30, 2012 | -332.29M |
| March 31, 2012 | -233.90M |
| December 31, 2011 | -218.08M |
| September 30, 2011 | 94.04M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-248.10M
Minimum
Mar 2020
812.00M
Maximum
Jun 2019
118.02M
Average
43.40M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
| Liquidia Corp | 43.25M |
| Esperion Therapeutics Inc | 50.46M |
| Vertex Pharmaceuticals Inc | -562.20M |
| Heron Therapeutics Inc | 54.11M |
| Aldeyra Therapeutics Inc | -1.270M |